A weekly diversity-action review turns an enrollment goal into operating evidence: source mix, site access, language needs, follow-up speed, screen-failure reasons, and decisions owned before the study falls behind.
In this guide
Key points
- Diversity planning should have a weekly operating review, not only an upfront planning document.
- The review should separate awareness, referral quality, site access, coordinator follow-up, screening conversion, and avoidable barriers.
- Sponsor updates should end with decisions: adjust source mix, support sites, review materials, improve handoffs, or investigate recurring blockers.
Make the plan visible every week
A diversity action plan becomes operational only when the recruitment team reviews evidence on a recurring cadence. The weekly meeting should show whether outreach is reaching the intended population and whether the site workflow can support the patients who respond.
FDA's Diversity Action Plan guidance page describes plans intended to improve enrollment of participants from underrepresented populations and notes the guidance is draft and not for implementation. That status matters: this article is not regulatory instruction. It is an operating template for recruitment teams that need to turn planning into measurable action.
Use a funnel view, not a headline count
Start with the full funnel: source, inquiry, coordinator review, first contact, completed prescreen, screening scheduled, screening completed, and enrollment status. The goal is to find where movement stops.
If a community clinic produces fewer inquiries but a higher completed-prescreen rate, it may be more valuable than a campaign that produces high volume and low contactability.
Add barrier notes without profiling patients
The weekly review should document operational barriers such as travel distance, appointment availability, language support, records readiness, technology access, and callback timing.
Keep the review aggregate and operational. Do not turn diversity reporting into unnecessary patient-detail collection, and do not use it to make assumptions about individual people.
End with a sponsor decision
Each review should end with a decision: change source mix, adjust callback coverage, improve referral partner instructions, review translated materials, add site support, or investigate a recurring screen-failure pattern.
TrialsNest can support this operating rhythm by connecting source tracking, coordinator follow-up, site blockers, and sponsor-facing recruitment visibility in one workflow. The useful output is not a prettier report; it is a clearer next action.
Illustrative example
Case-style example
A sponsor sees strong inquiry volume from a community referral partner but weak completed prescreens. The weekly review shows that the partner sends interested patients after hours, while the site only calls during a narrow midday window.
The sponsor reads the report as a source-quality problem and considers pausing the partner.
The team adds evening callback blocks, gives the partner a clearer handoff note, and reviews completed prescreens before changing source spend.
Operator note
If the weekly update only says enrollment is behind, it is too late in the funnel. The useful review shows where underrepresented patients are dropping and which team can act before the next reporting cycle.
Common mistakes
Counting only total inquiries
Raw inquiry volume can hide whether a source reaches the intended population, whether the site can follow up, and whether patients reach screening.
Treating outreach as the whole plan
Community outreach helps only when the handoff, scheduling capacity, language support, and site access are ready to receive the interest it creates.
Before you start
- Review source mix: Compare source volume, reviewable inquiries, completed prescreens, and screening progress by source instead of ranking channels by form fills.
- Review access barriers: Track repeated travel, timing, language, records, technology, and callback-window blockers that prevent interested patients from moving forward.
- Assign owner and next action: Every repeated barrier should have an owner: sponsor, site, coordinator lead, referral partner, materials reviewer, or operations lead.
- Which sources created reviewable inquiries this week, not just clicks?
- Where did patients drop before coordinator contact, prescreen, or screening visit?
- Which site barriers require sponsor action instead of more advertising?
Sources and editorial notes
Published .
Operational recruitment review guidance only. Diversity plans, study design, and regulatory submissions should follow sponsor, IRB, investigator, and legal review requirements.
- Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies — FDA
- ClinicalTrials.gov protocol data element definitions — ClinicalTrials.gov
This information is educational. Your study team makes medical, eligibility, and enrollment decisions.
See TrialsNest in action
Bring this workflow into one place.
Manage inquiries, follow-ups, records, and visits. Keep sponsors updated on progress.
Sponsor portfolio
39 / 50 enrolled78%
74 / 120 enrolled62%
9 / 10 enrolled90%
Keep reading
Clinical trial diversity planning before recruitment opens
A practical guide to clinical trial diversity planning through protocol review, site selection, logistics, and early enrollment measurement.
Clinical trial recruitment weekly report template
A weekly clinical trial recruitment report template for summarizing movement, source quality, site blockers, scheduled next steps, decisions needed, and owner follow-up.
Sponsor recruitment reporting guides and templates
Resources for sponsor and CRO teams comparing clinical trial recruitment reporting software, dashboard views, site blockers, source quality, and next actions.
Rescue planning for an under-enrolling clinical trial
Under-enrollment should be diagnosed before teams increase advertising spend. The constraint may be source quality, site follow-up, records blockers, eligibility ambiguity, visit burden, or sponsor decision lag.
